Items Tagged with 'Boston Scientific FDA'
BSX Reports Net Sales of $1.828 Billion
On July 26, 2012, Boston Scientific Corporation (NYSE: BSX) released financial results for the second quarter ended on June 30, 2012.
BSX Acquires Cameron Health for $150 Million
On June 8, 2012, Boston Scientific Corporation (NYSE: BSX) closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its product portfolio the world's first and only commercially available subcutaneous implantable cardioverter defibrillator, called the S-ICD® System.
BSX Receives FDA Approval
On June 4, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System.
BSX Recieves FDA Pacemaker Approval
On May 7, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™ cardiac resynchronization therapy pacemakers (CRT-P).
On February 22, 2012, Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack.
On December 8, 2011, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous Lead for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.
On November 30, 2011, Boston Scientific Corporation (NYSE: BSX) announced FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators to treat heart failure and sudden cardiac death.
Turnaround Investment Strategies
Distressed Investing Blog
Investors have found many things to dislike about banks, such as increasing regulation and low lending margins in these days of miniscule interest rates. I think the banks may be about to fare better, making them one of the few sectors that look cheap in the current market.
Your Financial Security is Serious Business...
so why should you trust The Turnaround Letter?
Ranked as #1 Performing Newsletter for 15-Yr. Returns: Turnaround Letter's 12.7% vs. S&P's 2.7%
28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
Diverse Monthly Stock Picks Personally Selected by George Putnam
Dividend Turnaround Stock Picks
In this MoneyShow.com "Daily Guru" feature interview,George details three key advantages of dividend-paying turnaround stocks—and names four timely value investing stock picks suitable for conservative investors looking to cash in!
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.